Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC.

MLA

Ma, Weijie, et al. “Small Molecule Tyrosine Kinase Inhibitors Modulated Blood Immune Cell Counts in Patients with Oncogene-Driven NSCLC.” Biomarker Research, 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1277077863&authtype=sso&custid=ns315887.

APA

Ma, W., Ma, W., Zeng, J., Chen, S., Lyu, Y., Toomey, K. A., Phan, C. T., Yoneda, K. Y., & Li, T. (2021). Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. Biomarker Research.

Chicago

Ma, Weijie, Weijie Ma, Jie Zeng, Shuai Chen, Yue Lyu, Kyra A Toomey, Chinh T Phan, Ken Y Yoneda, and Tianhong Li. 2021. “Small Molecule Tyrosine Kinase Inhibitors Modulated Blood Immune Cell Counts in Patients with Oncogene-Driven NSCLC.” Biomarker Research. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1277077863&authtype=sso&custid=ns315887.